Factory Price Ivermectin Raw Material Pharmaceutical API Levamisole Injection 10% CAS 14769-73-4

Name: Factory Price Ivermectin Raw Material Pharmaceutical API Levamisole Injection 10% CAS 14769-73-4
Brand: Hebei Veyong Pharmaceutical Co., Ltd.
SKU: 1963367222

Hebei, ChinaHebei Veyong Pharmaceutical Co., Ltd.

US$0.74

10,000-49,999 Pieces

US$0.71

50,000-99,999 Pieces

US$0.65

100,000+ Pieces

Product profile

Varieties

Parasite Disease Prevention Medicine

Component

Chemical Synthetic Drugs

Type

The First Class

Model NO.

injection

Pharmacodynamic Influential Factors

Incompatibility

Storage Method

Protected From Light and High Temperature

Veterinary Reg. No.

Factory

Yes

GMP

Yes

Sample

Yes

Transport Package

in Kraft Paper Carton

Specification

50ml/vial/box, 120boxes/carton

Trademark

Veyong, OEM, ODM

Origin

China

HS Code

300420

Production Capacity

3000L/Day

Company profile

Hebei Veyong Pharmaceutical Co., Ltd.Hebei, China

Business Type: Manufacturer/Factory, Group Corporation CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2003-02-01 CertifiedNearest Port: Tianjin PortAverage Response Time: ≤24h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHebei Veyong Pharmaceutical Co., Ltd. is a China-based veterinary pharmaceutical manufacturer established in 2002, with 363 employees, two production bases, more than 10 production lines, and a 36,500 m² manufacturing plant. Its capabilities cover veterinary APIs, preparations, premixes, feed additives, and related products including ivermectin and eprinomectin. The supplier reports ISO9001, ISO14001, ISO45001, multiple GMP certificates, an Ivermectin CEP certificate, and successful US FDA inspection. It has a provincial technical center, 15 R&D engineers, and documented production capacity for ivermectin and eprinomectin. The supplier also states that it provides pre-sales and after-sales service and exports to South America, Africa, Southeast Asia, and the Middle East. Evidence is insufficient to assess customization capability and customer cases specifically. Financial credibility cannot be fully assessed because financial statements and payment-related evidence are not provided.

Supplier typeThe supplier is identified as Hebei Veyong Pharmaceutical Co., Ltd., a China-based limited company and factory in the manufacturing industry. Its stated business covers R&D, production, and sales of veterinary APIs, preparations, premixed feeds, and feed additives, with two production bases.

CertificationsThe supplier explicitly reports ISO9001 certification, China GMP, Australia APVMA GMP, Ethiopia GMP, an Ivermectin CEP certificate, and a passed US FDA inspection. It also reports ISO14001 and ISO45001 management-system certificates, demonstrating broad documented quality, environmental, occupational-safety, and product-compliance credentials.

After-Sales capabilityVeyong states that it has professional registration, sales, and technical-service teams and provides pre-sales and after-sales service. Its stated export markets and reported order fulfillment within 15 working days in both off-peak and peak seasons further support an established service and delivery structure.

R&D capabilityVeyong reports a provincial technical center, an innovation-oriented R&D system for new veterinary drugs, and recognition as a technology-innovation-based veterinary enterprise. It also reports 15 R&D engineers, providing explicit evidence of dedicated research and development capability.

Production capacityThe supplier reports more than 10 production lines, two production bases, 12 preparation lines, and production of 13 API products. It specifically states annual capacities of 120 tons for ivermectin and 10 tons for eprinomectin, with a 36,500 m² manufacturing plant and order fulfillment within 15 working days in both stated seasons.